ArticleDiscover oncology2026
A bibliometric analysis of the research landscape of lenalidomide resistance in multiple myeloma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMultiple myeloma (MM), the second most common hematological malignancy, is often treated with lenalidomide. However, resistance to this cornerstone therapy inevitably develops in nearly all patients, adversely affecting treatment outcomes and prognosis. To map the knowledge landscape, this study aims to analyze publication trends and identify research hotspots in lenalidomide resistance in MM.
methodsA comprehensive search was conducted in the Web of Science Core Collection database from 2005 to 2025. Bibliometric analysis was performed using CiteSpace, VOSviewer, and the R package "bibliometrix" software to identify publication trends, collaborations, and research clusters.
resultsThis bibliometric analysis showed sustained growth in publications on MM and lenalidomide resistance. The USA accounted for the largest number of articles (961), followed by China (235) and Italy (183). Harvard University had the largest number of publications among institution (502) whereas Blood had the highest total citation count in this dataset (16,080). Author analysis identified Philippe Moreau as the researcher with the highest H-index. Keyword analysis revealed four major research clusters focusing on combination therapy, cellular mechanisms and apoptosis pathways, proteasome inhibitors, and monoclonal antibodies. Keyword burst analysis revealed "consensus", "phase 3", "open label", "survival outcomes", "oral ixazomib" and "multicenter" since 2020.
conclusionThis bibliometric analysis highlights the rapidly evolving field of lenalidomide resistance in MM. Future efforts should focus on developing next-generation agents against resistance, designing rational combination therapies targeting key pathways like signal transducer and activator of transcription 3 (STAT3)/ nuclear factor kappa-B (NF-κB), and establishing evidence-based treatment consensus to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.